Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
20.98 USD +4.33% Intraday chart for Longboard Pharmaceuticals, Inc. +2.04% +247.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding CI
Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $60 From $55, Maintains Overweight Rating MT
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating MT
Longboard Pharmaceuticals Closes $242 Million Public Offering MT
HC Wainwright Adjusts Price Target on Longboard Pharmaceuticals to $60 From $25, Keeps Buy Rating MT
Wedbush Raises Longboard Pharmaceuticals' PT to $32 From $22, Says Offering Removes Near-Term Cash Runway Overhang, Provides Resources to Advance Bexicaserin; Keeps Outperform Rating MT
Longboard Pharmaceuticals Prices $210 Million Stock Offering MT
Longboard Pharmaceuticals Launching Share Offering MT
Sector Update: Health Care Stocks Gain Late Afternoon MT
Longboard Pharmaceuticals Shares Surge After Positive Topline Results for Seizures Treatment MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Top Midday Gainers MT
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $55 From $35, Maintains Overweight Rating MT
Transcript : Longboard Pharmaceuticals, Inc. - Special Call
Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin in Participants with Developmental and Epileptic Encephalopathies CI
Guggenheim Raises Longboard Pharmaceuticals' Price Target to $32 From $16, Keeps Buy Rating MT
Wedbush Raises Longboard Pharmaceuticals' PT to $22 From $11, Says PACIFIC Data Readout Provides Best-Case Scenario for Bexicaserin (LP352); Keeps Outperform Rating MT
Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers CI
North American Morning Briefing : Traders Await -2- DJ
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Longboard Pharmaceuticals, Inc. - Analyst/Investor Day
Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Global BMI Index CI
Longboard Completes Enrollment in Study of LP352 for Treatment of Developmental, Epileptic Encephalopathies MT
Chart Longboard Pharmaceuticals, Inc.
More charts
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing medicines for neurological diseases. Its pipeline includes LP352 and LP659. LP352 is an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, CDKL5 deficiency disorder, SCN2A-related disorders, among others. LP659 is a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator for inflammatory neurological conditions. LP659 is designed to avoid the negative effects connected to the receptor subtypes 2 and 3, which is associated with serious, off-target cardiac, pulmonary, and cancer-related effects. It also has license to certain compounds including LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, and compounds targeting the 5-HT2A receptor, including nelotanserin.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
20.98 USD
Average target price
42.86 USD
Spread / Average Target
+104.28%
Consensus
  1. Stock
  2. Equities
  3. Stock Longboard Pharmaceuticals, Inc. - Nasdaq
  4. News Longboard Pharmaceuticals, Inc.
  5. Wedbush Starts Longboard Pharmaceuticals at Outperform With $14 Price Target